Ibandronsäure Stada (Ibandronic Acid)

Ibandronsäure Stada belongs to the bisphosphonate class and is used to manage diseases characterized by increased bone turnover.

• Osteoporosis (postmenopausal women): reduces the risk of vertebral and non‑vertebral fractures.
• Paget's disease of bone: normalises abnormal bone remodeling and alleviates bone pain.
• Bone metastases from solid tumours: lowers the incidence of skeletal‑related events such as fractures and spinal cord compression.

• Ibandronic Acid binds selectively to hydroxyapatite crystals at sites of active bone remodeling. When osteoclasts attach to these bound crystals, the drug is internalised, disrupting the mevalonate pathway, inducing osteoclast apoptosis and thereby decreasing bone resorption.

Ibandronsäure Stada may cause a range of adverse reactions.

Common Side Effects

• Upper gastrointestinal discomfort: nausea, dyspepsia or abdominal pain.
• Constipation or diarrhoea.
• Musculoskeletal pain: bone, joint or muscle aches.
• Headache.
• Transient flu‑like symptoms after the first dose.

Serious or Rare Side Effects

• Osteonecrosis of the jaw (ONJ).
• Atypical femur fracture.
• Severe hypersensitivity reactions, including rash or angioedema.
• Acute phase reaction: fever, chills, myalgia.
• Renal impairment, especially with rapid intravenous administration.

Before initiating therapy, several safety considerations should be addressed.

• Renal function assessment: evaluate creatinine clearance and avoid use in severe renal impairment.
• Calcium and vitamin D status: ensure adequate supplementation to reduce hypocalcaemia risk.
• Gastro‑oesophageal disorders: avoid in patients with active oesophageal inflammation or strictures.
• Pregnancy and lactation: contraindicated; advise effective contraception during treatment.
• Concomitant nephrotoxic drugs: monitor closely when combined with NSAIDs or aminoglycosides.
• Store at below 25°C: keep in the original packaging, protect from moisture and direct sunlight.

Ibandronsäure Stada can interact with several medicines, influencing its safety or effectiveness.

Major Interactions (Avoid)

• Concurrent use of other bisphosphonates or potent bone‑resorbing agents.
• Co‑administration with nephrotoxic agents (e.g., high‑dose NSAIDs, aminoglycosides) may exacerbate renal toxicity.

Moderate Interactions (Monitor Closely)

• Proton‑pump inhibitors or H2‑blockers: may reduce oral absorption of ibandronate.
• Calcium, antacids, or multivitamins containing aluminium/magnesium: should be taken at least 2 hours apart.
• Diuretics (especially thiazides): can affect calcium balance and increase hypocalcaemia risk.
• Corticosteroids: may augment bone loss, requiring closer monitoring of bone density.